Skip to content
Homepage
Author:
Vera Therapeutics
Posted Date:
June 5, 2026
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics
June 5, 2026
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy
Vera Therapeutics
June 2, 2026
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics
May 8, 2026
Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
Vera Therapeutics
May 8, 2026
Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference
Vera Therapeutics
May 4, 2026
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics
March 27, 2026
Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer
Vera Therapeutics
March 25, 2026
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics
March 6, 2026
Vera Therapeutics Appoints Christopher Hite to Board of Directors
Vera Therapeutics
March 5, 2026
Vera Therapeutics to Participate at Upcoming Investor Conferences
Vera Therapeutics
February 24, 2026
1
2
Next
